• Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Glenmark Share Price

    Glenmark Pharmaceuticals Share PriceGlenmark Pharmaceuticals

    Large Cap 17.6k Result
    ₹770.1
    -0.9 (-0.12%)
    As on 29 November, 2023 | 20:55 BSE: 532296 NSE: GLENMARKISIN: INE935A01035

    Glenmark Pharmaceuticals Performance

    Day Range

    • Low 764.50
    • High 777.40
    ₹ 770.1

    52 Week Range

    • Low 369.05
    • High 880.00
    ₹ 770.1
    • Open Price777.40
    • Previous Close771.00
    • Volume726023

    Start SIP in Glenmark Pharmaceuticals

    Start SIP

    Glenmark Pharmaceuticals Share Price

    • Over 1 Month 3.63%
    • Over 3 Month 1.79%
    • Over 6 Month 29.54%
    • Over 1 Year 75.7%

    Glenmark Pharmaceuticals Key Statistics

    P/E Ratio -110.7
    PEG Ratio 0.9
    Market Cap Cr 21,730
    Price to Book Ratio 2.2
    EPS 55.9
    Dividend 0.3
    Relative Strength Index 49.26
    Money Flow Index 51.71
    MACD Signal -1.77
    Average True Range 21.46

    Glenmark Pharmaceuticals F&O

    Glenmark Pharmaceuticals Futures
    Glenmark Pharmaceuticals Option Chain

    Glenmark Pharmaceuticals Investment Rating

    • Master Rating:

    • Glenmark Pharms. (Nse) has an operating revenue of Rs. 13,446.55 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 7% is okay, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 41%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 18% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 12% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 14 which is a POOR score indicating inconsistency in earnings, a RS Rating of 70 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 70 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Glenmark Pharmaceuticals Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 2,2332,1441,8752,1612,1531,8721,721
    Operating Expenses Qtr Cr 1,7631,6591,7211,7231,8261,4781,624
    Operating Profit Qtr Cr 471485218439382434162
    Depreciation Qtr Cr 50494746464542
    Interest Qtr Cr 58625956524074
    Tax Qtr Cr 87120-17615917720319
    Net Profit Qtr Cr 302272-137431423493206
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 9,2078,756
    Operating Expenses Annual Cr 6,7486,453
    Operating Profit Annual in Cr 1,4731,688
    Depreciation Cr 184160
    Interest Annual Cr 207236
    Tax Annual Cr 363340
    Net Profit Annual Cr 1,2091,998
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 1,4741,216
    Cash from Investing Activity Annual Cr -431-897
    Cash from Financing Annual Activity Cr -978-305
    Net Cash Flow Annual Cr 6414
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 17,87716,739
    Fixed Assets Annual Cr 1,9181,861
    Total Non Current Assets Annual Cr 20,20118,512
    Total Current Assets Annual Cr 4,3854,403
    Total Assets Annual Cr 24,58622,914
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 634593
    ROE Annual % 712
    ROCE Annual % 1111
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3028
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 3,2073,4023,3013,4643,3122,7202,961
    Operating Expenses Qtr Cr 2,7452,7702,7692,8442,7542,3462,556
    Operating Profit Qtr Cr 462631605620622432463
    Depreciation Qtr Cr 141155147162156147132
    Interest Qtr Cr 12111210997836087
    Tax Qtr Cr 56160-8818020219797
    Net Profit Qtr Cr -8223-428291260193156
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 13,30712,472
    Operating Expenses Annual Cr 10,7129,985
    Operating Profit Annual in Cr 2,2782,320
    Depreciation Cr 611487
    Interest Annual Cr 350298
    Tax Annual Cr 491448
    Net Profit Annual Cr 297942
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 6251,109
    Cash from Investing Activity Annual Cr -528-333
    Cash from Financing Annual Activity Cr -77-520
    Net Cash Flow Annual Cr 19255
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 9,4749,087
    Fixed Assets Annual Cr 7,3806,837
    Total Non Current Assets Annual Cr 9,4988,801
    Total Current Assets Annual Cr 9,8748,282
    Total Assets Annual Cr 19,37217,083
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 349334
    ROE Annual % 310
    ROCE Annual % 1416
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2020
    Invest in Glenmark Pharmaceuticals

    Glenmark Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹770.1
    -0.9 (-0.12%)
    pointer
    • Bullish Moving Average
    • ___
    • 6
    • Bearish Moving Average
    • ___
    • 10
    • 20 Day
    • ₹771.35
    • 50 Day
    • ₹772.45
    • 100 Day
    • ₹747.28
    • 200 Day
    • ₹676.71
    • 20 Day
    • ₹766.68
    • 50 Day
    • ₹782.76
    • 100 Day
    • ₹775.56
    • 200 Day
    • ₹652.10

    Glenmark Pharmaceuticals Resistance and Support

    PIVOT
    ₹770.67
    Resistance
    First Resistance 776.83
    Second Resistance 783.57
    Third Resistance 789.73
    RSI 49.26
    MFI 51.71
    MACD Single Line -1.77
    MACD 0.31
    Support
    First Resistance 763.93
    Second Resistance 757.77
    Third Resistance 751.03

    Glenmark Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 753,205 32,365,219 42.97
    Week 1,141,860 32,348,880 28.33
    1 Month 1,136,767 33,955,240 29.87
    6 Month 1,298,203 40,192,370 30.96

    Glenmark Pharmaceuticals Result Highlights

    Glenmark Pharmaceuticals Synopsis

    NSE-Medical-Generic Drugs

    Glenmark Pharma is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 8220.66 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2023. Glenmark Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982.
    Market Cap 21,730
    Sales 8,478
    Shares in Float 14.95
    No of funds 288
    Yield 0.32
    Book Value 1.22
    U/D Vol ratio 0.8
    LTDebt / Equity 15
    Alpha 0.2
    Beta 0.84

    Glenmark Pharmaceuticals

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 46.65%46.65%46.65%46.65%
    Mutual Funds 7.3%5.36%5.43%5.64%
    Insurance Companies 2.44%3.18%4.41%4.48%
    Foreign Portfolio Investors 24.79%25.51%22.47%23.19%
    Financial Institutions/ Banks 0.2%0.2%0.2%0.2%
    Individual Investors 14.84%15.2%16.9%16.72%
    Others 3.78%3.9%3.94%3.12%

    Glenmark Pharmaceuticals Management

    Name Designation
    Mr. Glenn Saldanha Chairman & Managing Director
    Mrs. Cherylann Pinto Executive Director - Corporate Affairs
    Mr. V S Mani Executive Director & Global CFO
    Mr. Rajesh V Desai Non Executive Director
    Dr. Brian W Tempest Non Executive Director
    Mr. Dipankar Bhattacharjee Non Executive Director
    Mr. Bernard Munos Non Executive Director
    Mr. Sridhar Gorthi Non Executive Director
    Mrs. B E Saldanha Non Executive Director
    Mr. D R Mehta Non Executive Director
    Ms. Saira Ramasastry Non Executive Director

    Glenmark Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Glenmark Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2023-11-10 Quarterly Results
    2023-08-11 Quarterly Results
    2023-05-19 Audited Results & Final Dividend
    2023-02-10 Quarterly Results
    2022-11-11 Quarterly Results

    Glenmark Pharmaceuticals MF Shareholding

    Name Amount(cr)
    HDFC Balanced Advantage Fund Growth 63,981
    HDFC Mid-Cap Opportunities Fund Growth 47,846
    Kotak Equity Arbitrage Fund Growth 28,958
    SBI Arbitrage Opportunities Fund Regular Growth 22,370
    Aditya Birla Sun Life Flexi Cap Fund Growth 17,029

    Glenmark Pharmaceuticals FAQs

    What is Share Price of Glenmark Pharmaceuticals ?

    Glenmark Pharmaceuticals share price is ₹770 As on 29 November, 2023 | 20:41

    What is the Market Cap of Glenmark Pharmaceuticals ?

    The Market Cap of Glenmark Pharmaceuticals is ₹21729.8 Cr As on 29 November, 2023 | 20:41

    What is the P/E ratio of Glenmark Pharmaceuticals ?

    The P/E ratio of Glenmark Pharmaceuticals is -110.7 As on 29 November, 2023 | 20:41

    What is the PB ratio of Glenmark Pharmaceuticals ?

    The PB ratio of Glenmark Pharmaceuticals is 2.2 As on 29 November, 2023 | 20:41

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.